Figure 1From: Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancerProgression-free survival of patients in the Ce-SOX group and the SOX group estimated by Kaplan–Meier. Cum, cumulative.Back to article page